RT Journal Article
SR Electronic
T1 Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 72
OP 79
DO 10.1136/gutjnl-2012-303376
VO 63
IS 1
A1 Mirthe Emilie van der Valk
A1 Marie-Josée J Mangen
A1 Max Leenders
A1 Gerard Dijkstra
A1 Ad A van Bodegraven
A1 Herma H Fidder
A1 Dirk J de Jong
A1 Marieke Pierik
A1 C Janneke van der Woude
A1 Mariëlle J L Romberg-Camps
A1 Cees HM Clemens
A1 Jeroen M Jansen
A1 Nofel Mahmmod
A1 Paul C van de Meeberg
A1 Andrea E van der Meulen-de Jong
A1 Cyriel Y Ponsioen
A1 Clemens JM Bolwerk
A1 J Reinoud Vermeijden
A1 Peter D Siersema
A1 Martijn GH van Oijen
A1 Bas Oldenburg
A1 on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis
YR 2014
UL http://gut.bmj.com/content/63/1/72.abstract
AB Objective The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivity losses in a large cohort of IBD patients. Design Crohn's disease (CD) and ulcerative colitis (UC) patients from seven university hospitals and seven general hospitals were invited to fill-out a web-based questionnaire. Cost items were derived from a 3 month follow-up questionnaire and categorised in outpatient clinic, diagnostics, medication, surgery and hospitalisation. Productivity losses included sick leave of paid and unpaid work. Costs were expressed as mean 3-month costs per patients with a 95% CI obtained using non-parametric bootstrapping. Results A total of 1315 CD patients and 937 UC patients were included. Healthcare costs were almost three times higher in CD as compared with UC, €1625 (95% CI €1476 to €1775) versus €595 (95% CI €505 to €685), respectively (p<0.01). Anti-TNFα use was the main costs driver, accounting for 64% and 31% of the total cost in CD and UC. Hospitalisation and surgery together accounted for 19% and <1% of the healthcare costs in CD and 23% and 1% in UC, respectively. Productivity losses accounted for 16% and 39% of the total costs in CD and UC. Conclusions We showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy. Hospitalisation and surgery accounted only for a minor part of the healthcare costs.